Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.65 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.55 |
| ▸ | PYGL | P06737 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 4/20 | 0.44 |
| ▸ | ABL1 | P00519 | 3/20 | 0.43 |
| ▸ | SRC | P12931 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.37 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1243825 | 0.83 | DAO (0.59) | DAOHRH4PYGLCYP1A2GAA | |
| SCHEMBL8217192 | 0.81 | DAO (0.71) | DAOHRH4PYGL | |
| SCHEMBL1680315 | 0.80 | KDM4E (0.47) | DAOHRH4GAAGLAKDM4E | |
| SCHEMBL1244615 | 0.79 | DAO (1.00) | DAOHRH4PYGLKDM4EMAPT | |
| SCHEMBL2333687 | 0.77 | DAO (0.71) | DAOHRH4PYGLABL1MAPK1 | |
| SCHEMBL3173158 | 0.77 | DAO (0.71) | DAOHRH4PYGLMAPK1MAPT | |
| SCHEMBL6635824 | 0.77 | DAO (0.65) | DAOHRH4PYGLMAPK1GAA | |
| SCHEMBL1243954 | 0.75 | DAO (0.64) | DAOHRH4CYP1A2XDHABL1 | |
| SCHEMBL8223574 | 0.74 | DAO (0.61) | DAOHRH4PYGLGAAKMT2A | |
| SCHEMBL13395531 | 0.73 | XDH (0.44) | CYP1A2XDHABL1SRCGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626860-A1 | FUSED PYRROLYL-SULFONAMIDE COMPOUNDS | ReWind Therapeutics NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| US-20250129091-A1 | THIENOPYRROLOTRIAZINE COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2025-04-24 | — | — | US | disclosed |
| EP-4482841-A1 | THIENOPYRROLOTRIAZINE COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE | Sanofi (FR) | 2025-01-01 | — | — | EP | disclosed |
| CN-118843632-A | Thienopyrrolotriazine compounds, their preparation and their therapeutic use | 赛诺菲 | 2024-10-25 | — | — | CN | disclosed |
| WO-2024115733-A1 | FUSED PYRROLYL-SULFONAMIDE COMPOUNDS | REWIND THERAPEUTICS NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| US-20240175141-A1 | BIOBASED AND BIODEGRADABLE CORROSION INHIBITION COMPOSITION | ZestBio, Inc. | 2024-05-30 | — | — | US | disclosed |
| WO-2024081967-A2 | BIOBASED AND BIODEGRADABLE CORROSION INHIBITION COMPOSITION | ZestBio, Inc. (US) | 2024-04-18 | — | — | WO | disclosed |
| CN-114478537-B | Cyclic amide parallel-ring compound and medical application thereof | 上海拓界生物医药科技有限公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2023156643-A1 | THIENOPYRROLOTRIAZINE COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2023-08-24 | — | — | WO | disclosed |
| CN-114478537-A | Cyclic amide-fused ring compound and medical use thereof | 上海拓界生物医药科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2011100324-A1 | CANNABINOID RECEPTOR AGONISTS | Ironwood Pharmaceuticals Inc. (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011095556-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | N.V. ORGANON (NL) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011071996-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011006066-A1 | CB RECEPTOR AGONISTS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011006066-A1 | CB RECEPTOR AGONISTS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-7696240-B2 | Fused pyrrole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-04-13 | — | — | US | disclosed |
| CN-101351446-A | Novel fused pyrrole derivatives | HOFFMANN LA ROCHE (CH) | 2009-01-21 | — | — | CN | disclosed |
| EP-1966134-A1 | NOVEL FUSED PYRROLE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007068621-A1 | NOVEL FUSED PYRROLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| US-20070142452-A1 | Fused pyrrole derivatives | HOFFMANN-LA ROCHE INC. | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129091-A1 | THIENOPYRROLOTRIAZINE COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE | TPMT, TYMP, TBXA2R | DAO 3353/4885HRH4 357/4885PYGL 4383/4885 |
| US-20070142452-A1 | Fused pyrrole derivatives | CMA1, PREP, CPA3 | DAO 829/4885HRH4 138/4885PYGL 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.